ReleaseWire Connect

Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company engaged in the research and development of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections, is down in trading today, following the huge rally in the previous trading session.

Celgene Corporation (NASDAQ: CELG), a biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancers and immune-inflammatory related diseases, have risen sharply in trading today after the company announced its financial outlook and preliminary 2012 results.

Signet Jewelers Ltd. (NYSE: SIG), a specialty retail jeweler in the U.S. and U.K., is up sharply in mid-day trading today. The stock is gaining momentum after the company announced its sales results for the nine-week period ended December 29, 2012. The company said that its same-store sales during the nine-week period rose 3.3%, led by the U.S. division.

Perion Networks Ltd. (NASDAQ: PERI), operating as a digital media company, is seeing a huge rally in mid-day trading today after the company announced its revenue estimates for 2012 and guidance for 2013. The company said that it expects 2012 revenue at $61 million, up 64% from 2011. For 2013, the company expects revenue to exceed $110 million. EBITDA for 2013 is expected to be at least $26 million.

Cisco Systems Inc. (NASDAQ: CSCO) traded in the range of $20.16 and $20.42 during its latest trading session. The stock had opened at $20.34 and closed at $20.29, down 0.94 percent from its previous close of $20.48. Cisco Systems has its first support level at $19.93 while it faces the resistance at $20.42. If the stock breaches this level, it may go as high as $20.63.

Dell Inc. (NASDAQ: DELL) stock closed its latest trading session at $11.06, up 0.82 percent from its previous close of $10.97. However, its today’s volume of 25.78 million shares was higher than its usual trading volume of 22.058 million shares. The stock opened the session at $10.90 and touched its highest price point at $11.09. Dell stock’s lowest price point for the session stood at $10.84. The stock’s MACD chart shows neutral trend in the short term. Its first resistance level is at $11.48. Upon breaching this level, the stock may rise to $12.03. Dell reported the departure of its mergers head Dave Johnson.

Research in Motion Limited (NASDAQ: RIMM) traded in the range of $11.72 and $12.14 during its latest trading session. The stock recorded the volume of 21.253 million shares, significantly lower than its average daily trading volume of 34.51 million shares. The stock had opened at $12.05 and closed at $11.95, in line with its previous close of $11.95. It is currently trading above its 6 days EMA of 11.84 and has its first support level at $11.79. In the intermediate time period, the stock may test $12.29 resistance level. Research in Motion is a Canada based mobile communication company.

Apple Inc. (NASDAQ: AAPL) traded in the range of $515.20 and $529.30 during its latest trading session. The stock had opened at $522.05 and closed at $523.90, down 0.59 percent from its previous close of $527. Apple recorded the volume of 17.262 million shares. The stock has overall bearish trend as per its MACD chart. It is also trading below its 6 days EMA of $529 and 20 days EMA of $532. Apple is a technology company and deals in computers, laptops, mobiles and other electronic gadgets. The company is based out of Cupertino.

NVIDIA Corporation (NASDAQ: NVDA) stock closed its latest trading session at $12.77, down 2.89 percent from its previous close of $13.15. Its latest trading volume has been recorded at 15.267 million shares. The stock has made up movement with high volume and thus shows bullish trend. It is likely to go up to $13.05 level in the coming trading sessions. Its second resistance level is at $13.26.

Advanced Cell Technology, Inc. (OTCQB: ACTC) Robert Lanza, M.D., chief scientific officer of ACTC recently stated “They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don’t contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.” Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced that chairman and CEO Gary Rabin will present at Biotech Showcase 2013 on Tuesday, Jan. 8, in San Francisco.